These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 2431197)

  • 1. Conservative drug therapy and walking exercise in stage IIb peripheral arterial occlusion disease.
    Kiesewetter H; Jung F; Blume J; Bulling B; Gerhards M
    Klin Wochenschr; 1986 Oct; 64(20):1061-9. PubMed ID: 2431197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hemorheologic therapy in peripheral arterial occlusive disease].
    Kiesewetter H; Jung F
    Fortschr Med; 1984 Oct; 102(37):921-4. PubMed ID: 6500451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemodilution with medium molecular weight hydroxyethyl starch in patients with peripheral arterial occlusive disease stage IIb.
    Kiesewetter H; Blume J; Jung F; Spitzer S; Wenzel E
    J Intern Med; 1990 Feb; 227(2):107-14. PubMed ID: 1688914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Conservative treatment of arterial occlusive diseases with naftidrofuryl hydrogen oxalate (author's transl)].
    Ratschow R
    MMW Munch Med Wochenschr; 1976 Sep; 118(36):1131-4. PubMed ID: 823407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of regular physical training in a supervised class and additional intravenous prostaglandin E1 and naftidrofuryl infusion therapy in patients with intermittent claudication--a controlled study.
    Diehm C; Kühn A; Strauss R; Hübsch-Müller C; Kübler W
    Vasa Suppl; 1989; 28():26-30. PubMed ID: 2609241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg.
    Adhoute G; Bacourt F; Barral M; Cardon JM; Chevalier JM; Cuny A; Gillet M; Juhan C; Leguay G; Marion J
    Angiology; 1986 Mar; 37(3 Pt 1):160-7. PubMed ID: 3518547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Iso- and hypervolemic hemodilution with hydroxyethyl starch (HES 200/.05 10%) in patients with II b peripheral arterial occlusive disease].
    Kiesewetter H; Blume J; Jung F; Spitzer S; Gerhards M; Waldhausen P; Wenzel E
    Wien Med Wochenschr; 1989 Sep; 139(17):396-401. PubMed ID: 2480029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of naftidrofuryl in patients with intermittent claudication.
    Karnik R; Valentin A; Stöllberger C; Slany J
    Angiology; 1988 Mar; 39(3 Pt 1):234-40. PubMed ID: 3281516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Transcutaneous measures of oxygen partial pressure and capillaroscopic parameters as affected by naftidrofuryl in patients with obliterative arteriopathies, Fontaine stages II-IV].
    Ranft J; Heidrich H; Lammersen T
    J Mal Vasc; 1987; 12(1):78-81. PubMed ID: 3559415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemodilution in patients with peripheral arterial occlusive disease.
    Kiesewetter H; Jung F; Erdlenbruch W; Wenzel E
    Int Angiol; 1992; 11(3):169-75. PubMed ID: 1281205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naftidrofuryl in chronic arterial disease. Results of a controlled multicenter study.
    Trübestein G; Böhme H; Heidrich H; Heinrich F; Hirche H; Maass U; Mörl H; Rudofsky G
    Angiology; 1984 Nov; 35(11):701-8. PubMed ID: 6388425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease.
    Barradell LB; Brogden RN
    Drugs Aging; 1996 Apr; 8(4):299-322. PubMed ID: 8920176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hyper- or isovolemic hemodilution in patients with stage II peripheral arterial occlusive disease].
    Kiesewetter H; Jung F; Blume J; Spitzer S; Birk A
    Acta Med Austriaca; 1991; 18 Suppl 1():23-7. PubMed ID: 1719729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of intravenous naftidrofuryl on the microcirculation of patients in stages III and IV of arterial occlusive disease].
    Abendroth D; Sunder-Plassmann L
    Vasa Suppl; 1988; 24():33-7. PubMed ID: 3212601
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hemodilution in patients with multiple morbidity and peripheral arterial occlusive disease].
    Kiesewetter H; Blume J; Jung F; Spitzer S; Bach R; Birk A; Schieffer H; Wenzel E
    Schweiz Med Wochenschr; 1989 Dec; 119(51):1862-7. PubMed ID: 2481883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of oxygen inhalation and intravenous naftidrofuryl on the transcutaneous partial oxygen pressure in ischaemic lower limbs.
    Mustapha NM; Jain SK; Dudley P; Redhead RG
    Prosthet Orthot Int; 1984 Dec; 8(3):135-8. PubMed ID: 6522254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of naftidrofuryl on breathlessness and exercise tolerance in chronic bronchitis.
    Williams AJ; Osman J; Skinner C
    Thorax; 1982 Aug; 37(8):617-9. PubMed ID: 7179191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vagal stimulation - a new possibility for conservative treatment of peripheral arterial occlusion disease].
    Payrits T; Ernst A; Ladits E; Pokorny H; Viragos I; Längle F
    Zentralbl Chir; 2011 Oct; 136(5):431-5. PubMed ID: 22009541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative study of low molecular dextran or hydroxyethyl starch as a volume substitute in hemodilution therapy].
    Kiesewetter H; Jung F; Blume J; Bulling B; Franke RP
    Klin Wochenschr; 1986 Jan; 64(1):29-37. PubMed ID: 2419635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Naftidrofuryl in stages III and IV of peripheral arterial occlusive disease].
    Horsch S
    Vasa Suppl; 1988; 24():38-43. PubMed ID: 3212602
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.